tiprankstipranks
Trending News
More News >
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
US Market
Advertisement

Unicycive Therapeutics (UNCY) AI Stock Analysis

Compare
710 Followers

Top Page

UNCY

Unicycive Therapeutics

(NASDAQ:UNCY)

Select Model
Select Model
Select Model
Underperform 28 (OpenAI - 4o)
Rating:28Underperform
Price Target:
Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.
Positive Factors
Patent Issuance
The new patent strengthens Unicycive's intellectual property portfolio, enhancing its competitive position and supporting future development and partnership opportunities.
Orphan Drug Designation
Orphan Drug Designation can provide market exclusivity and regulatory benefits, potentially accelerating development and commercialization efforts for UNI-494.
Equity Improvement
Improvement in equity indicates some recovery in financial health, providing a more stable foundation for future financing and operational activities.
Negative Factors
Financial Leverage
High financial leverage increases risk, as it may limit the company's ability to invest in growth opportunities and respond to financial challenges.
Negative Cash Flow
Negative cash flow indicates operational inefficiencies and reliance on external funding, which can hinder long-term sustainability and growth.
Revenue Generation Challenges
The absence of revenue growth poses significant hurdles for achieving profitability and sustaining operations, impacting the company's long-term viability.

Unicycive Therapeutics (UNCY) vs. SPDR S&P 500 ETF (SPY)

Unicycive Therapeutics Business Overview & Revenue Model

Company DescriptionUnicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
How the Company Makes MoneyUnicycive Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves conducting research and development to bring its therapeutic products through clinical trials and eventually to market. Key revenue streams include potential sales from its approved drugs, licensing agreements, and partnerships with other pharmaceutical companies. Unicycive may also receive milestone payments and royalties from collaborations or licensing deals that leverage its proprietary technologies and drug candidates.

Unicycive Therapeutics Financial Statement Overview

Summary
Unicycive Therapeutics faces substantial financial challenges typical of early-stage biotech companies. The absence of revenue growth and consistent net losses present significant hurdles. While there is some improvement in equity, the company's heavy reliance on debt and external financing poses financial risks. Management must focus on operational efficiencies and sustainable revenue generation to improve financial health.
Income Statement
10
Very Negative
Unicycive Therapeutics has struggled with revenue generation, as evidenced by zero total revenue in the latest year, and has consistently reported negative net income. The company's EBIT and EBITDA margins are negative, indicating ongoing operational challenges. Despite a previous revenue presence, the lack of sustainable growth is concerning.
Balance Sheet
25
Negative
The balance sheet shows significant liabilities compared to equity, with a debt-to-equity ratio that suggests high financial leverage. However, the equity position has improved from negative to positive, indicating some recovery. The equity ratio remains low, highlighting a heavy reliance on debt.
Cash Flow
30
Negative
Free cash flow is negative, reflecting cash consumption for operations, which is a common challenge in early-stage biotech firms. Positive financing cash flow indicates reliance on external funding. The operating cash flow to net income ratio suggests inefficiencies in converting earnings to cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue568.00K0.00675.00K951.00K0.000.00
Gross Profit-112.00K-428.00K675.00K944.00K-1.00K0.00
EBITDA-39.61M-36.23M-30.18M-18.05M-8.98M0.00
Net Income-31.50M-36.73M-30.54M-18.06M-10.63M-2.51M
Balance Sheet
Total Assets30.00M31.67M14.19M2.82M18.74M204.00K
Cash, Cash Equivalents and Short-Term Investments22.33M26.14M9.70M455.00K16.58M0.00
Total Debt476.00K773.00K811.00K155.00K306.00K2.51M
Total Liabilities13.57M24.24M18.00M3.28M2.26M2.88M
Stockholders Equity16.43M7.43M-3.81M-466.00K16.48M-2.67M
Cash Flow
Free Cash Flow-33.19M-28.65M-18.30M-15.65M-5.80M-1.46M
Operating Cash Flow-33.12M-28.57M-18.28M-15.65M-5.77M-1.46M
Investing Cash Flow-68.00K-72.00K-12.00K-2.00K-29.00K0.00
Financing Cash Flow13.74M45.09M27.54M-471.00K22.38M1.44M

Unicycive Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.74
Price Trends
50DMA
4.26
Negative
100DMA
5.15
Negative
200DMA
5.70
Negative
Market Momentum
MACD
-0.14
Positive
RSI
33.46
Neutral
STOCH
17.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Negative. The current price of 3.74 is below the 20-day moving average (MA) of 4.11, below the 50-day MA of 4.26, and below the 200-day MA of 5.70, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 33.46 is Neutral, neither overbought nor oversold. The STOCH value of 17.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNCY.

Unicycive Therapeutics Risk Analysis

Unicycive Therapeutics disclosed 57 risk factors in its most recent earnings report. Unicycive Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Unicycive Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
91.07M-0.55-185.15%1.80%
46
Neutral
104.42M-1.62-77.40%-42.94%
45
Neutral
281.93M-4.96-100.00%72.53%
45
Neutral
95.68M-3.14-66.16%-87.65%11.76%
44
Neutral
225.69M-3.87-100.00%-62.44%
28
Underperform
$68.00M-3987.11%68.02%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
UNCY
Unicycive Therapeutics
3.74
-0.43
-10.31%
ADVM
Adverum Biotechnologies
4.31
-2.63
-37.90%
IMAB
I-MAB
3.52
2.37
206.09%
ADAG
Adagene
2.02
-0.22
-9.82%
TCRX
TScan Therapeutics
1.78
-3.26
-64.68%
SGMT
Sagimet Biosciences, Inc. Class A
7.14
4.32
153.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 08, 2025